Complications of Intravesical Therapy for Urothelial Cancer of the Bladder

Journal of Urology

Volumn 175, Issue 6, 2006, Pages 2004-2010

  Koya, Madhusudan P ^a   Simon, Michael A ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

administration; bladder; bladder neoplasms; complications; intravesical; Mycobacterium bovis

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2B INTERFERON; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BCG VACCINE; CEFTRIAXONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOSERINE; DOXORUBICIN; EPIRUBICIN; ETHAMBUTOL; INTERFERON; ISONIAZID; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENAZOPYRIDINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID; TUBERCULOSTATIC AGENT;

ANEMIA; AORTODUODENAL FISTULA; ARTHRALGIA; ARTHRITIS; BACTERIAL STRAIN; BLADDER CANCER; BLADDER CARCINOMA; BLADDER DISEASE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CARDIOTOXICITY; CHILL; CHOROIDITIS; CLINICAL TRIAL; CONTACT DERMATITIS; CONTRACTURE; CYSTITIS; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ADMINISTRATION ROUTE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSURIA; ECZEMA; EYE DISEASE; FATIGUE; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRANULOMATOSIS; HEMATURIA; HEPATITIS; HUMAN; HYPOTENSION; IMMUNE COMPLEX NEPHRITIS; INFLAMMATION; JAUNDICE; KIDNEY ADENOMA; LEUKOPENIA; LUPUS VULGARIS; LYMPHADENITIS; MAINTENANCE THERAPY; MALAISE; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOBACTERIOSIS; MYCOTIC ANEURYSM; NONHUMAN; ORCHITIS; PAIN; PELVIS PAIN SYNDROME; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATITIS; RESPIRATORY FAILURE; REVIEW; SEPSIS; SIDE EFFECT; SKIN EXFOLIATION; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION; URETHRA DISEASE; URINARY DYSFUNCTION; URINARY TRACT INFECTION; URINARY URGENCY; UROGENITAL TRACT CANCER; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 33646381092     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00264-3     Document Type: Review

References (44)

1. Cancer Facts and Figures 2005 (2005), American Cancer Society, Atlanta
2. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., Algaba F., and Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164 (2000) 680
3. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., and Mason M.D. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer. a meta-analysis of randomized trials. BJU Int 93 (2004) 485
4. Pawinski A., Sylvester R., Kurth K.H., Bouffioux C., Van Der Meijden A., Parmar M.K.B., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156 (1996) 1934
5. Smith Jr. J.A., Labasky R.F., Montie J.E., Rowland R.G., Crockett A.T.K., and Fracchia J.A. Bladder Cancer Clinical Guidelines Panel. Report on the Management of Nonmuscle Invasive Bladder Cancer [Stages Ta, T1 and Tis] (1999), American Urological Association, Baltimore
6. Oosterlinck W., Lobel B., Jakse G., Malmstrom P.U., Stockle M., Sternberg C., et al. Guidelines on bladder cancer. Eur Urol 41 (2002) 105
7. Soloway, M., Hautmann, R., Solsona, E., Sylvester, R., Van der meijden, A., Sternberg, C. et al: International consultation on bladder cancer. SIU/WHO/ICUD. Unpublished data
8. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180
9. Lamm D.L., van der Meijden A.P., Akaza H., Brendler C.B., Hedlund P.O., Mizutani Y., et al. Intravesical chemotherapy and immunotherapy. how do we assess their effectiveness and what are their limitations and uses?. Int J Urol 2 (1995) 23 suppl.
10. Witjes J.A., v d Meijden A.P., Collette L., Sylvester R., Debruyne F.M., van Aubel A., et al., EORTC GU Group and the Dutch South East Cooperative Urological Group, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. Urology 52 (1998) 403
11. Sylvester R.J., van der Meijden A.P.M., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer. a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964
12. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder. a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124
13. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671
14. Rivera P., Orio M., Hinostroza J., Venegas P., Pastor P., Gorena M., et al. Nuestra experiencia con instilaciones de 1 mg de vacuna BCG en cancer vesical etapa T1. Actas Urol Esp 23 (1999) 757
15. O'Donnell M.A., Krohn J., and DeWolf W.C. Salvage intravesical therapy with interferon-α 2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166 (2001) 1300
16. O'Donnell M.A., Lilli K., Leopold C., and the National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888
17. Lamm D.L. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19 (1992) 565
18. Molina J.M., Rabian C., D'Agay M.F., and Modai J. Hypersensitivity systemic reaction following intravesical bacillus Calmette-Guerin. successful treatment with steroids. J Urol 147 (1992) 695
19. Lamm D.L., van der Meijden A.P.M., Morales A., Brosman S.A., Catalona W.J., Herr H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147 (1992) 596
20. Mukamel E., Konichezky M., Engelstein D., Cytron S., Abramavici A., and Servadio C. Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations. J Urol 144 (1990) 1399
21. DeHaven J.I., Traynellis C., Riggs D.R., Ting E., and Lamm D.L. Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol 147 (1992) 738
22. Durek C., Rusch-Gerdes S., Jocham D., and Böhle A. Interference of modern antibacterials with bacillus Calmette-Guerin viability. J Urol 162 (1999) 1959
23. Nieder A.M., Sved P.D., Stein J.P., Skinner D.G., and Soloway M.S. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guerin-induced bladder contractures. Urology 65 (2005) 909
24. Torti F.M., Shortliffe L.D., Williams R.D., Pitts W.C., Kempson R.L., Ross J.C., et al. Alpha-interferon in superficial bladder cancer. a Northern California Oncology Group Study. J Clin Oncol 6 (1988) 476
25. Malmstrom P.U. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89 (2002) 681
26. Jimenez-Cruz J.F., Vera-Donoso C.D., Leiva O., Pamplona M., Rioja-Sanz L.A., Martinez-Lasierra M., et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1). multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 50 (1997) 529
27. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer. results with intravesical BCG and Interferon combination therapy. Can J Urol 10 (2003) 1790
28. Belldegrun A.S., Franklin J.R., O'Donnell M.A., Gomella L.G., Klein E., Neri R., et al. Superficial bladder cancer. the role of interferon-alpha. J Urol 159 (1998) 1793
29. Sylvester R.J., van der Meijden A.P.M., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder. a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86
30. Sylvester R.J., Oosterlinck W., and van der Meijden A.P.M. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer. a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186
31. Huland H., Kloppel G., Feddersen I., Otto U., Brachmann W., Hubmann H., et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma. final evaluation of a prospective multicenter study with 419 patients. J Urol 144 (1990) 68
32. Eijsten A., Knonagel H., Hotz E., Brutsch H.P., and Hauri D. Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. Br J Urol 66 (1990) 386
33. de Groot A.C., and Conemans J.M. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic Mitomycin C. Contact Dermatitis 24 (1991) 201
34. Zein T.A., Friedberg N., and Kim H. Bone marrow suppression after intravesical mitomycin C treatment. J Urol 136 (1986) 459-460
35. Cliff A.M., Romaniuk C.S., and Parr N.J. Perivesical inflammation after early Mitomycin C instillation. BJU Int 85 (2000) 556
36. Nieuwenhuijzen J.A., Bex A., and Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol 43 (2003) 711
37. Doherty A.P., Trendell-Smith N., Stirling R., Rogers H., and Bellringer J. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int 83 (1999) 420
38. Thrasher J.B., and Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 19 (1992) 529
39. Ali-El-Dein B., El-Baz M., Aly A.N.M., Shamaa S., and Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1). a randomized prospective study. J Urol 158 (1997) 68
40. Rischmann P., Desgrandchamps F., Malavaud B., and Chopin D.K. BCG intravesical instillations. recommendations for side-effects management. Eur Urol 37 (2000) 33 suppl.
41. Bassi P., Nicola P., Spinadin R., Carando R., Pagano F., and Papagallo G.L. Low dose vs standard dose BCG therapy of superficial bladder cancer. final results of a phase 3 randomized trial. Eur Urol 35 (1999) 152 suppl. abstract
42. Martínez-Piñeiro J.A., Jiménez León J., Martínez-Piñeiro Jr. L., Fiter L., Mosteiro J.A., Novarro J., et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa. a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143 (1990) 502
43. Vegt P.D., van der Meijden A.P.M., Sylvester R., Brausi M., Holtl W., and de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of the European Organization for Research and Treatment of Cancer protocol 30911. J Urol 157 (1997) 1246
44. Rintala E., Jauhiainen K., Alfthan O., Hansson E., Juusela H., Kanerva K., et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol 20 (1991) 19